Clinical Trial

Transcranial Photobiomodulation for Bipolar Depression

Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
This study the effectiveness and safety of light therapy device targeted at the brain using a wearable device, the Vielight RX Gamma as a treatment for bipolar depression. Up to forty patients with bipolar disorder will be enrolled into the study and will either receive active treatment with the Vielight RX Gamma or sham (inactive device). They will be administered the devices in clinic 5days/week for 6 weeks. Changes in disease symptoms, cognitive function, pain, quality of life and rest EEG changes will be assessed.
Trial Details
NCT Number NCT07510646
Lead Sponsor Vielight Inc.
Conditions Bipolar, Bipolar Disorder (BD), Bipolar Disorder Depression
Enrollment 40 participants
Start Date 2026-07-01
Primary Completion 2027-07-01 (estimated)
Study Completion 2027-07-01 (estimated)
Updated on ClinicalTrials.gov 2026-04-03